Evaluation of the effect of the carrier of polymorphic variants of the SLCO1B1 gene on efficacy and safety in patients during treatment with statins

The number of patients receiving statins is increasing every year. Considering the need for life-long intake of drugs of this group, the problem of improving safety and efficacy of their use becomes especially important. There is a large amount of data on the influence of various genetic factors on...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	N. A. Rumyantsev, Yu. V. Olefir, V. G. Kukes
פורמט:	Artigo
שפה:	Russo
יצא לאור:	Ministry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» 2018-02-01
סדרה:	Безопасность и риск фармакотерапии
נושאים:	ген slco1b1 эффективность и безопасность фармакогенетика миопатия рабдомиолиз статины персонализированная медицина gene slco1b1 efficacy and safety pharmacogenetics myopathy rhabdomyolysis statins personalized medicine
גישה מקוונת:	https://www.risksafety.ru/jour/article/view/87
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!